Brief: Rigel Pharmaceuticals Completes Transfer Of Gavreto New Drug Application
24/06/2024 21:16
June 24 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL PHARMACEUTICALS COMPLETES TRANSFER OF GAVRETO®
(PRALSETINIB) NEW DRUG APPLICATION
* RIGEL PHARMACEUTICALS INC -GAVRETO WILL BE AVAILABLE FROM
RIGEL
IN U.S. BEGINNING JUNE 27, 2024
Source text for Eikon: ID:nPn2hz6Gfa
Further company coverage: RIGL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)